Ovarian Cancer Market Forecasts to 2030 – Global Analysis By Type (Germ Cell Tumors, Epithelial Tumors, Primary Peritoneal Cancer and Stromal Tumors), Therapeutic Treatment, Diagnostic Test, End User and By Geography

Ovarian Cancer Market Forecasts to 2030 – Global Analysis By Type (Germ Cell Tumors, Epithelial Tumors, Primary Peritoneal Cancer and Stromal Tumors), Therapeutic Treatment, Diagnostic Test, End User and By Geography

According to Stratistics MRC, the Global Ovarian Cancer Market is accounted for $3.18 billion in 2023 and is expected to reach $16.01 billion by 2030 growing at a CAGR of 26.0% during the forecast period. One kind of cancer that starts in the female reproductive system, the ovaries is called ovarian cancer. The ovaries are where eggs and female hormones are produced and this disease, which ranks seventh in the globe among women, sometimes stays undiagnosed until it has progressed to the abdomen and pelvic. A combination of imaging tests (ultrasound, CT scan, MRI), blood tests (CA-125 tumor marker), pelvic examinations, and occasionally a biopsy to confirm the presence of cancer cells are used in the diagnosis process.

According to the American Cancer Society (ACS) report in January 2022, ovarian cancer was the ninth most common cancer and the fifth leading cause of cancer death among women in the United States.

Market Dynamics:

Driver:

Increased prevalence of ovarian cancer

Both developed and developing countries' expanding economies are fuelling the spread of healthcare. They are therefore contributing to the advancement of the worldwide market. Ovarian cancer incidence is predicted to raise, the number of older women in the population, the ease of using new treatments and therapies, and growing healthcare costs are all likely to contribute to the growth of the worldwide market. Ovarian cancer has increased in frequency as the female population has aged. The industry is driven by rising rates of ovarian cancer, new drug and treatment introductions, rising healthcare costs, and rising government financing.

Restraint:

Lack of specific screening tests

Due to the fact that ovarian cancer is frequently discovered later in the disease's progression, treatment choices are limited and results are generally worse. One major obstacle that prevents prompt identification and intervention is the absence of effective early screening techniques. Moreover, certain subtypes of ovarian cancer may remain resistant to traditional medicines such as chemotherapy or targeted treatments, even with breakthroughs in treatment. Successful care of resistant or recurrent ovarian cancer is threatened by the scarcity of viable medications thus impeding the growth of the market.

Opportunity:

Rising healthcare awareness

Women are more likely to identify the signs and risk factors of ovarian cancer when there is greater awareness. Increased awareness encourages people to seek medical care sooner, which results in rapid diagnosis and intervention and may help identify the illness at an earlier, more manageable stage. Better communication between patients and healthcare professionals is fostered by increased awareness. It is increasingly common for patients to talk to their doctors about symptoms or risk factors that they find troubling, which makes it easier for prompt assessments and relevant diagnostic procedures.

Threat:

Complexity and heterogeneity of ovarian cancer

Treatment difficulties are a result of the many subtypes and molecular traits of ovarian cancer. Treatments that work for one subtype might not work as well for another. Treatment regimen customization for individual patients based on their unique genetic profile and subtype can be challenging and call for individualized methods. The complexity of ovarian cancer makes it difficult to establish consistent treatment plans. Moreover, it is challenging to provide clear recommendations when treatment techniques are inconsistent, which might result in care that is inconsistent and make it challenging to identify the best course of action for each patient.

Covid-19 Impact

Numerous standard checkups and diagnostic procedures including those for ovarian cancer were cancelled or postponed during the outbreak and decreased early cancer detection may have resulted in later diagnoses due to reduced access to healthcare facilities and prioritizing of COVID-19 care. The pandemic had an impact on several clinical studies looking at new ovarian cancer therapy thus trial enrollment declined, and several that were already underway had their modifications or temporary pauses implemented to guarantee participant safety and adherence to pandemic-related regulations.

The germ cell tumors segment is expected to be the largest during the forecast period

The germ cell tumors segment is estimated to have a lucrative growth, as these are more frequent in younger women and often have a better prognosis, although being less common than other kinds of ovarian cancer (such as epithelial ovarian cancer). Since younger women are frequently affected by germ cell tumors, efforts are made to maintain fertility if possible while undergoing therapy. In this population, surgical methods that efficiently cure the malignancy while preserving reproductive function are frequently investigated which enhances the market.

The hormone therapy segment is expected to have the highest CAGR during the forecast period

The hormone therapy segment is anticipated to witness the highest CAGR growth during the forecast period, because for some ovarian cancers, especially low-grade serous ovarian carcinoma, hormone treatment may be an option. According to certain studies, a small proportion of individuals with LGSC may benefit somewhat from hormone therapies like aromatase inhibitors or hormonal receptor blockers to slow the growth of their tumors. Additionally, hormone therapy may be investigated as a palliative option in cases of ovarian cancer that is recurring or resistant, where traditional therapies have been tried and tested and are no longer working to control symptoms or reduce the disease's development.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Furthermore, the market is growing due to an increase in spending on customized medicine and the use of high-tech processes to enhance the development of medications for ovarian cancer and a large population base, the existence of unmet medical demands, and an increase in the region's disposable income all contribute to the market's growth.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, as North America held the greatest revenue share of dominating the market and ovarian cancer can be diagnosed and treated earlier in the region because to its sophisticated medical facilities and well-developed healthcare infrastructure. Patients' growing knowledge has resulted in higher screening and detection rates. Furthermore, there are a large number of academic centers, research facilities, and pharmaceutical businesses in North America that are dedicated to creating novel cancer treatments. The American Cancer Society reports that the sixth most common cause of cancer-related deaths in women is ovarian cancer which drives the growth of the market in this region.

Key players in the market

Some of the key players profiled in the Ovarian Cancer Market include Abbvie Inc, Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Merck KGaA, Novogen, Inc., Oasmia Pharmaceutical Inc., Pfizer, Inc., Siemens Healthineers AG, Tesaro Inc. and Vivesto AB

Key Developments:

In November 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® (rivaroxaban [2.5 mg twice daily plus aspirin 100 mg once daily]) over standard of care (aspirin alone).

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. The company’s new UK STEM equity programme aims to help reduce the significant barriers to entry faced by women and young girls, people from lower socio-economic backgrounds and Black communities

In October 2023, GSK and Zhifei announce exclusive strategic vaccine partnership in China. Partnership will significantly extend availability of Shingrix in China with co-promotion to healthcare professionals and over 30,000 points of vaccination

Types Covered:
• Germ Cell Tumors
• Epithelial Tumors
• Primary Peritoneal Cancer
• Stromal Tumors

Therapeutic Treatments Covered:
• Radiation Therapy
• Chemotherapy
• Hormone Therapy
• Targeted Therapy
• Surgery
• Other Therapeutic Treatments

Diagnostic Tests Covered:
• Ultrasound
• Computed Tomography (C.T.) Scans
• Barium Enema X-Ray
• Chest X-Ray
• Positron Emission Tomography (PET) Scan
• Magnetic Resonance Imaging (MRI) Scans
• Other Diagnostic Tests

End Users Covered:
• Diagnostic Centers
• Hospitals
• Online Pharmacies
• Drug Stores
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements